Search Medical Condition
Please enter condition
Please choose location from dropdown

Szeged, Hungary Clinical Trials

A listing of Szeged, Hungary clinical trials actively recruiting patients volunteers.

RESULTS

Found (121) clinical trials

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

Phase

0.47 miles

Learn More »

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD. This study will look at the PK, efficacy, immunogenicity, safety, and tolerability in participants who take vedolizumab. The study will enroll approximately 80 ...

Phase

0.47 miles

Learn More »

Impact of Humira Therapy on Ocular Inflammation Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate Posterior and Panuveitis in Routine Clinical Practice

This study aims at evaluating real life effectiveness of originator adalimumab (Humira) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU ...

Phase N/A

0.47 miles

Learn More »

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira and BI 695501 in Patients With Plaque Psoriasis.

The primary objective of the trial is to assess the PK similarity between patients receiving Humira continuously vs those who alternate between BI 695501 and Humira, in patients with moderate-to-severe chronic plaque psoriasis. The secondary objectives of this trial are to descriptively compare the safety, immunogenicity and efficacy profiles between ...

Phase

0.47 miles

Learn More »

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Phase

0.47 miles

Learn More »

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.

Phase

0.47 miles

Learn More »

Evaluation of Dupilumab in Children With Uncontrolled Asthma

The total study duration per patient will be up to 69 weeks, consisting of a screening period of 3-5 weeks, a randomized treatment period of 52 weeks and a post-treatment period of 12 weeks.

Phase

0.47 miles

Learn More »

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

This will be a phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs, who previously tolerated and demonstrated biochemical control on both treatments. The core ...

Phase

0.47 miles

Learn More »

Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Part 1: Approximately 66 subjects will be randomized in a 1:1:1 ratio to the following dose groups Zimura Dose Administration 1 Zimura Dose Administration 2 Sham Administration 1 Part 2: Approximately 135 subjects will be randomized in a 1:2:2 ratio to the following dose groups Zimura Dose Administration 3 Zimura ...

Phase

0.47 miles

Learn More »

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 followed by an optional 16-week randomized dose escalation treatment period and a continuous treatment period ...

Phase

0.47 miles

Learn More »